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 Cytochrome P450 (CYP) enzymes catalyze the formation 
of biologically active epoxy- and hydroxy-metabolites of 
long-chain PUFAs ( 1 ). Traditionally, and in line with the 
prevalence of n-6 PUFAs in the “Western diet”, arachidonic 
acid (AA) (20:4 n-6) has been considered as the main pre-
cursor and the corresponding metabolites were catego-
rized as a subclass of eicosanoids ( 2 ). CYP-eicosanoid 
formation is also known as the “third branch of the AA cas-
cade,” complementary to the previously discovered cyclooxy-
genase (COX)- and lipoxygenase (LOX)-initiated pathways 
of prostanoid and leukotriene formation ( 3, 4 ). 
 Physiologically important AA-derived CYP-eicosanoids in-
clude a set of regio- and stereoisomeric epoxyeicosatrienoic 
acids (EETs) and 20-HETE ( 2, 5 ). EETs and 20-HETE play 
partially opposing roles in the regulation of vascular, renal, 
and cardiac function ( 6–9 ). The contribution of EETs to 
cardiovascular function is infl uenced by the soluble epox-
ide hydrolase (sEH) that metabolizes EETs to less potent 
dihydroxyeicosatrienoic acids (DHETs) ( 10 ). Imbalances in 
CYP-eicosanoid formation are linked to the development of 
endothelial dysfunction and hypertension; ischemia-induced 
injury of the heart, kidney and brain; infl ammatory disor-
ders; and atherosclerosis ( 11–17 ). 
 Recent studies demonstrated that the same CYP isoforms 
that epoxidize or hydroxylate AA, also effi ciently metabolize 
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allowed);  ii ) BMI   30;  iii ) more than one marine fi sh meal per 
week or Omega-3 Index   6 ( 32 ); and  iv ) prior diagnosis of dys-
lipidemia. Occasional intake of drugs including nonsteroidal 
anti-infl ammatory drugs (NSAIDs) was documented at each visit. 
Only two participants reported the use of NSAIDs, taken shortly 
before (2 × 200 mg ibuprofen) or 1 week after starting EPA/DHA 
supplementation (1 × 200 mg ibuprofen). The study was per-
formed in accordance with the Declaration of Helsinki, current 
institutional guidelines, and good clinical practice. Our Institu-
tional Review Board approved the study and written informed 
consent was obtained from all participants before entry. 
 Study design 
 The “OMEICOS study” (EudraCT identifi er: 2009-013458-33) 
was conducted at the Experimental and Clinical Research Center 
(ECRC), Berlin, Germany, between December 2009 and Decem-
ber 2010 . The primary aim of OMEICOS was to analyze the effect 
of dietary omega-3 fatty acid supplementation on the profi le of 
main CYP-, LOX-, and COX-dependent metabolites in blood 
plasma and urine. From the 38 volunteers initially screened, 20 
fulfi lled all criteria for study inclusion. After analysis of basal pa-
rameters, dietary omega-3 fatty acid supplementation was started. 
Study participants received one capsule OMACOR® (Abbott 
GmbH, Germany) per day (containing 460 mg EPA and 380 mg 
DHA as ethyl esters) from weeks 1 to 4, and two capsules OMA-
COR® per day (980 mg EPA and 760 mg DHA as ethyl esters) 
from weeks 5 to 8. Afterwards, omega-3 supplementation was 
stopped and the participants were followed-up for another 8 weeks 
(weeks 9–16). Study visits and assessment of clinical and bio-
chemical parameters were done before (basal), after week 1, 
week 4, week 8, week 9, and week 16 . 
 Assessment 
 Clinical standard parameters (body weight, blood pressure, 
ECG) and food intake were documented at each study visit in a 
standardized fashion. Blood samples (after overnight fasting) and 
24 h-urine samples were taken at each study visit. Glucose, lipo-
proteins, and triglycerides were determined by standard methods 
in a certifi ed clinical laboratory. Blood (EDTA-plasma) and urine 
samples were stored at   80°C for eicosanoid profi ling. 
 Determination of eicosanoid profi les 
 Plasma samples (500   l) were subjected to alkaline hydrolysis 
and subsequent solid phase extraction (SPE) was performed ex-
actly as described previously ( 22 ). Urine samples (2 ml) were treated 
with 0.2 mg   -glucuronidase from  Escherichia coli in 0.1 mol/l 
phosphate buffer (pH 6.8) containing 1 mg/ml BSA for 2 h at 
37°C. After that, pH was adjusted to 6.0 with acetic acid and the 
metabolites were extracted using the same SPE procedure as with 
plasma. The capacity of blood cells to produce leukotrienes and 
other LOX metabolites, as well as thromboxanes, was determined 
after incubating fresh blood samples (4.5 ml) with 50   M of the 
calcium ionophore A23187 for 30 min at 37°C as described previ-
ously ( 33 ). The free metabolites present after calcium ionophore 
stimulation were directly extracted via SPE without prior alkaline 
hydrolysis. 
 LC-MS/MS analysis of the extracted metabolites was performed 
using an Agilent 6460 Triple Quad mass spectrometer with JetStream 
ion source (Agilent Technolgies, Santa Clara, CA) coupled with an 
Agilent 1200 HPLC system (degasser, binary pump, well plate sam-
pler, thermostated column compartment). The HPLC system was 
equipped with a Phenomenex Kinetex column (150 mm × 2.1 mm, 
2.6   m; Phenomenex, Aschaffenburg, Germany). Chromatography 
was done under gradient conditions with acetonitrile/0.1% formic 
acid in water as mobile phase. Gradient was started at 5% acetonitrile, 
fi sh oil n-3 PUFAs such as EPA (20:5 n-3) and DHA (22:6 
n-3) ( 18–22 ). CYP2C and CYP2J isoforms convert AA to 
EETs, EPA to epoxyeicosatetraenoic acids (EEQs), and DHA 
to epoxydocosapentaenoic acids (EDPs). The   -3 double 
bond distinguishing EPA and DHA from AA is the preferred 
site of attack of most of the epoxygenases, resulting in the 
formation of 17,18-EEQ and 19,20-EDP as main metabo-
lites. CYP4A and CYP4F isoforms, hydroxylating AA to 20-
HETE, metabolize EPA to 20-hydroxyeicosapentaenoic acid 
(HEPE) and DHA to 22-hydroxydocosahexaenoic acid 
(HDHA). CYP1A1, CYP2E1, and other isoforms that con-
vert AA predominantly to 19-HETE show pronounced   -3 
epoxygenase activities with EPA and DHA. Like EETs, EEQs 
and EDPs can also be degraded to the corresponding 
vicinal diols [dihydroxyeicosatetraenoic acids (DHEQs) 
and dihydroxydocosapentaenoic acids (DHDPs)] by sEH-
mediated hydrolysis ( 23 ). 
 The currently known biological activities of EPA- and DHA-
derived CYP metabolites partially resemble those of their AA-
derived counterparts, appear in part unique, or may even 
produce opposite effects ( 24 ). The epoxy-metabolites of all 
three PUFAs share vasodilatory properties, whereby the po-
tencies of EEQs and EDPs may largely exceed those of EETs 
in some vascular beds ( 18, 25 ). Anti-infl ammatory effects 
were fi rst revealed for 11,12- and 14,15-EET but are also ex-
erted by EPA-epoxides, as exemplifi ed by 17,18-EEQ ( 26, 27 ). 
17,18-EEQ and 19,20-EDP inhibit the Ca 2+ - and isoprotere-
nol-induced increased contractility of neonatal cardiomyo-
cytes, indicating that these metabolites may act as endogenous 
antiarrhythmic agents ( 22 ). Whereas certain EET regioiso-
mers promote tumor angiogenesis and metastasis, 19,20-EDP 
and other regioisomeric DHA-epoxides inhibit these crucial 
events in cancerogenesis ( 28, 29 ). These fi ndings suggest 
that CYP metabolites may serve as mediators in a variety of 
the benefi cial effects attributed to fi sh oil n-3 PUFAs, such as 
protection against cardiovascular disease, sudden cardiac 
death, and tumor development ( 30, 31 ). 
 Based on the substrate specifi city of recombinant CYP 
isoforms, we supposed that the profi le of physiologically 
active CYP-eicosanoids is extensively modulated in vivo by 
changing the dietary n-6/n-3 PUFA ratio. We proved this 
hypothesis fi rst in rats, where we found a clear shift from 
AA- to EPA- and DHA-derived epoxy- and   -hydroxy-
metabolites in all major organs and tissues upon dietary 
EPA/DHA supplementation ( 22 ). We have now expanded 
our studies to humans and analyzed the effect of EPA/DHA 
supplementation on the profi le of circulating and urinary 
CYP-eicosanoids in a trial with 20 healthy volunteers. Simul-
taneously, we also determined the levels of various LOX- 
and COX-dependent metabolites to gain insight into the 
relative susceptibility of the three branches of the human 
AA cascade to changes in the dietary n-6/n-3 PUFA ratio. 
 MATERIALS AND METHODS 
 Participants of the study 
 Healthy volunteers (men and women) with an age between 18 and 
60 years were included. Main exclusion criteria were:  i ) permanent 
medication (only thyroid hormone substitution and contraception 
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given as mean ± SEM. To test for the differences in response to 
dietary intervention, we analyzed our data by a general linear 
model for repeated measurements followed by a post hoc test 
based on estimated marginal means with a Holm step-down Bon-
ferroni procedure for correction of  P values. To test for gender 
differences, a  t -test for independent variables was applied.  P < 
0.05 was defi ned as statistically signifi cant. Associations between 
parameters were determined using Pearson or Spearman Rho 
correlation analysis. 
 RESULTS 
 Basic characteristics of the participants 
 Ten healthy men and ten healthy women participated 
in this study. Their mean age was 32 ± 8 years (males) and 
38 ± 6 years (females), and their BMI was 24.9 ± 2.7 kg/m 2 
(males) and 25.5 ± 3.8 kg/m 2 (females); see  Table 1 for 
further characteristics of the participants. These subjects 
were selected out of a total of 38 volunteers using an Omega-
3 Index >6 as exclusion criterion, i.e., EPA + DHA com-
prised less than 6% of the total fatty acids in RBCs of the 
subjects included ( Fig. 1A ). If not specifi cally stated other-
wise, we did not observe statistically signifi cant differences 
in the response of males and females to EPA/DHA supple-
mentation and thus report the data as means for the whole 
group of the participants. 
 Changes in RBC fatty acid composition upon dietary 
EPA/DHA supplementation 
 EPA/DHA supplementation caused a time- and dose-de-
pendent increase of the Omega-3 Index in all subjects, ex-
cept one male who remained at baseline RBC (EPA + DHA) 
level for unknown reasons and was not included in the fur-
ther analysis. The maximal increase of the Omega-3 Index 
was observed 8 weeks after starting EPA/DHA supplementa-
tion, i.e., after the participants ingested one Omacor® cap-
sule (480 mg EPA + 360 mg DHA) daily for the fi rst 4 weeks 
and two capsules daily in the subsequent 4 weeks ( Fig. 1B ). At 
this time point, the Omega-3 Index reached 8.4 ± 0.2 com-
pared with 4.9 ± 0.2 at baseline. The individually achieved 
increased to 55% after 0.5 min, to 69% after 14.5 min, and to 95% 
after 14.6 min. The fl ow rate was 0.3 ml/min during the run time of 
20 min. The injection volume was 7.5   l. Drying gas was adjusted at 
250°C/10 l/min, sheath gas at 380°C/12 l/min. Capillary and noz-
zle voltage were optimized at   4,500 V and   1,500 V, respectively . A 
complete list of the metabolites analyzed, as well as the correspond-
ing conditions for multiple reaction monitoring, is given in supple-
mentary Table I. The internal standards added to the samples before 
extraction included 10 ng each of 20-HETE- d 6, 14,15-EET- d 8, 14,15-
DHET -d 11, prostaglandin E2 (PGE2)-d4, leukotriene B4 (LTB4)-d5, 
and 15-HETE- d 8 (Cayman Chemical, Ann Arbor, MI) and served 
for the quantifi cation of groups of similar metabolites . Calibration 
curves for the quantifi cation of individual metabolites were estab-
lished based on the changes in the relative peak area in response to 
different target compound/internal standard-concentration ratios. 
Linearity was  r 2 > 0.99 over a range from 1 to 20 ng absolute for any 
compound. 
 Determination of fatty acid profi les 
 Red blood cell (RBC) fatty acid compositions were analyzed 
according to the HS-Omega-3 Index methodology as described 
previously ( 32 ). Fatty acid methyl esters were generated by acid 
transesterifi cation and analyzed by gas chromatography using a 
GC2010 gas chromatograph (Shimadzu, Duisburg, Germany) 
equipped with a SP2560 100 m column (Supelco, Bellefonte, PA) 
using hydrogen as carrier gas. Fatty acids were identifi ed by com-
parison with a standard mixture of fatty acids characteristic of 
erythrocytes. The Omega-3 Index is given as EPA plus DHA ex-
pressed as a percentage of total identifi ed fatty acids after re-
sponse factor correction. The coeffi cient of variation for EPA 
plus DHA was 5%. Analyses were quality-controlled according to 
DIN ISO 15189. 
 Sample size and statistical analysis 
 Prior to data analysis, a frequency distribution of the Omega-3 
Index, including all screened individuals, was performed (Graph-
Pad Prism 5.0). Out of 38 volunteers, 20 subjects were selected 
for the study fulfi lling the criterion of an Omega-3 Index below 6. 
The data from participant Omeicos26 was excluded from analysis 
due to noncompliance to the study protocol, giving a total of 
n = 19 for the subsequent per-protocol analysis. 
 Statistical analyses were performed with PASW Statistics 18, 
SPSS Inc. All data were tested for normal distribution and are 
 TABLE 1. Participant clinical parameters 
Parameters
Supplementation
Basal (week 0) OM-3 a  (2 g) (week 8) Follow-up (week 16)
Age (years)
 Male 31.3 ± 2.5 — —
 Female 38.0 ± 1.8 — —
Body weight (kg)
 Male 79.9 ± 5.6 80.8 ± 6.1 81.2 ± 6.2
 Female 68.4 ± 4.6 68.2 ± 4.6 68.0 ± 4.6
BMI (kg/m 2 )
 Male 24.9 ± 1.0 24.9 ± 1.0 24.9 ± 1.0
 Female 25.5 ± 1.3 25.5 ± 1.3 25.5 ± 1.3
Heart rate (bpm) 64.4 ± 2.1 67.4 ± 2.1 67.9 ± 2.1
Systolic blood pressure (mmHg) 123.2 ± 2.9 121.3 ± 2.9 121.2 ± 2.9
Diastolic blood pressure (mmHg) 75.5 ± 1.7 72.0 ± 1.7 73.4 ± 1.7
Total cholesterol (mmol/l) 5.2 ± 0.2 5.6 ± 0.2 5.2 ± 0.2
LDL (mmol/l) 3.1 ± 0.2 3.4 ± 0.2 3.2 ± 0.2
HDL (mmol/l) 1.4 ± 0.1 1.5 ± 0.1 1.4 ± 0.1
Triglycerides (mmol/l) 1.5 ± 0.2 1.1 ± 0.2 1.2 ± 0.2
All values are expressed as mean ± SEM.
 a OM-3, EPA/DHA-supplement as described in Materials and Methods.
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PUFAs (EPA + DHA) compared with those derived from 
AA. We included the regioisomeric epoxy-metabolites as 
well as the corresponding vicinal diols resulting from sEH-
mediated hydrolysis of the primary epoxy-metabolites and 
calculated this parameter as: [(EEQs + DHEQs) + (EDPs + 
DHDPs)]/(EETs + DHETs); see supplementary Table III 
for a complete set of the primary data for the weeks 0, 8, 
and 16. At baseline, the participants showed a mean plasma 
omega-3-epoxyeicosanoid index of 0.6 ± 0.03, i.e., the lev-
els of AA-derived metabolites exceeded those derived from 
(EPA + DHA) nearly twice. This ratio was rapidly and al-
most completely inversed upon dietary EPA/DHA supple-
mentation ( Fig. 2A ). The omega-3-epoxyeicosanoid index 
reached a peak value of 2.1 ± 0.15 at week 8, and returned 
nearly to baseline after discontinuation of EPA/DHA 
supplementation. 
 Despite these massive changes in the relative abundance 
of AA-, EPA-, and DHA-derived metabolites, the principal 
regioisomeric composition within each of the metabolite 
groups remained largely constant ( Fig. 2B ). Among the 
AA-derived metabolites, the 5,6-, 8,9-, 11,12-, and 14,15-
regioisomers contributed to the total (EET + DHET) lev-
els with relative percentages of 38:30:14:18 at week 0, 
peak values ranged between 6.7 and 10.7 and strongly corre-
lated with the product of the baseline Omega-3 Index and 
the dose per kg of body weight ( Fig. 1C ). Simultaneously with 
the increase in RBC EPA and DHA levels, the contents of AA 
(20:4 n-6), linoleic acid (C18:2 n-6), and oleic acid (C18:1 
n-9) were signifi cantly decreased ( Fig. 1D ). After discontinu-
ing EPA/DHA supplementation, the Omega-3 Index imme-
diately started to decline, but still remained signifi cantly 
elevated for the following eight weeks (6.6 ± 0.2) compared 
with the low baseline values ( Fig. 1B ). 
 Over the whole study period, the relative ratio of AA, 
EPA, and DHA changed from 1:0.04:0.25 at baseline (week 0), 
to over 1:0.15:0.38 after maximal EPA/DHA supplementa-
tion (week 8), to 1:0.07:0.35 at the end of the posttreat-
ment period (16 weeks); compare supplementary Table 
II for the complete RBC fatty acid compositions at these 
three stages of the study. 
 Changes in the CYP-eicosanoid profi le upon dietary 
EPA/DHA supplementation 
 We introduced the “omega-3-epoxyeicosanoid index” as 
a parameter that refl ects the relative abundance of CYP-
epoxygenase-dependent metabolites derived from n-3 
 Fig.  1. Effects of EPA/DHA supplementation on the Omega-3 Index and fatty acid composition in RBCs. 
A: Frequency distribution of the basal Omega-3 Index in the prescreened group of 38 healthy volunteers. 
Twenty subjects with an Omega-3 Index   6 (dashed line) were included into the study. B: Time- and dose-
dependent changes of the Omega-3 Index during the whole course of the study. C: Correlation of the 
Omega-3 Index achieved after 8 weeks of EPA/DHA supplementation with the product of the baseline 
Omega-3 Index and the dose per kilogram of body weight. D: Changes in the abundance of individual fatty 
acids comparing their percentages of total fatty acid in RBCs at week 8 and week 0 of EPA/DHA supplemen-
tation. Data are given as mean ± SEM, n = 19. A general linear model for repeated measurements was used 
for analysis (B, D) and signifi cant changes are indicated as: * P < 0.05 versus basal level [week 0 (W0)] and 
# P < 0.05 versus maximum treatment [week 8 (W8)]. For dosage dependency (C), a Pearson correlation was 
performed:  r = 0.599,  P < 0.01. 
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unaffected over the whole study period. 20-HEPE was un-
detectable in 7 out of 19 participants at baseline, but was 
clearly formed in all subjects after EPA/DHA supplemen-
tation and reached maximal levels between 0.4 and 
0.9 ng/ml at week 8. 22-HDHA was low at baseline (0.1 ± 
0.04 ng/ml), increased almost 6-fold after maximal EPA/
DHA supplementation, and declined to baseline levels 
during the follow-up period ( Fig. 3 ). 
 Similar pronounced changes were also observed in the 
urinary metabolite profi les (supplementary Table IV). All 
CYP-epoxygenase products were predominantly excreted 
after being hydrolyzed to the corresponding vicinal diols 
(compare supplementary Table IV). At all stages of the 
study, 8,9-DHET was the predominant AA-derived metab-
olite in the urine followed by 14,15-DHET. Among the 
EPA-derived vicinal diols, 17,18-DHEQ followed by 5,6-
DHEQ was most prominent, whereas 7,8- and 10,11-DHDP 
predominated among the DHA-derived regioisomers. 
EPA/DHA supplementation increased the total urinary 
concentration of EPA- and DHA-derived vicinal diols more 
than 2.5-fold at week 8 compared with baseline, without 
38:30:13:19 at week 8, and 40:30:13:18 at week 16. The 
EPA-derived 5,6-, 8,9-, 11,12-, 14,15-, and 17,18-regioiso-
mers (EEQs + DHEQs) occurred in ratios of 49:2:2:9:39 
(week 0), 50:3:3:12:32 (week 8), and 51:2:3:9:36 (week 16). 
The regioisomeric composition of the DHA-derived 7,8-, 
10,11-, 13,14-, 16,17-, and 19,20-regioisomers (EDPs + DH-
DPs) was 26:10:7:33:23 (week 0), 27:10:8:33:22 (week 8), 
and 31:11:8:30:26 (week 16 ). EPA/DHA supplementation 
for 8 weeks slightly, but signifi cantly, decreased the AA-
derived 5,6-, 8,9-, and 11,12-regioisomers, increased each of 
the regioisomeric EPA-derived metabolites almost 4-fold, 
and doubled the levels of all regioisomeric DHA-derived 
metabolites ( Fig. 2B ). Over the whole study, the relative 
plasma levels of EPA- and DHA-derived metabolites com-
pared with AA-derived metabolites strongly correlated with 
the respective precursor fatty acid ratios ( Figs. 2C, D ). 
 EPA/DHA supplementation also infl uenced the forma-
tion of   -hydroxylase products ( Fig. 3 ). At baseline, plasma 
20-HETE levels exceeded those of 20-HEPE and 22-HDHA 
7- to 9-fold. 20-HETE was detectable in all participants, 
ranged between 0.3 and 2.3 ng/ml, and remained largely 
 Fig.  2. Effect of EPA/DHA supplementation on the profi le of circulating CYP - epoxygenase metabolites. A: 
Time- and dose-dependent changes of the CYP-epoxyeicosanoid index during the whole course of the study. 
B: Regioisomeric composition of epoxygenase products derived from AA, EPA, and DHA at baseline [week 0 
(W0)], after maximal EPA/DHA supplementation [week 8 (W8)], and after discontinuation of supplemen-
tation [week 16 (W16)]. C: Correlation of the relative plasma levels of EPA- and AA-derived metabolites with 
the EPA/AA precursor fatty acid ratio. D: Correlation of the relative plasma levels of DHA- and AA-derived 
metabolites with the DHA/AA precursor fatty acid ratio. Metabolite levels are given as the sum of the primary 
CYP-epoxygenase products and the corresponding vicinal diols produced by sEH-mediated hydrolysis of the 
primary epoxides. Total metabolite levels (free + esterifi ed) were determined after alkaline hydrolysis. Data 
are given as mean ± SEM, n = 19. A general linear model for repeated measurements was used for analysis 
(A, B) and signifi cant changes are indicated as: * P < 0.05 versus basal level (W0) and # P < 0.05 versus maxi-
mum treatment (W8). For relative effi ciencies, a Pearson correlation was performed: y = 8.60x   0.06;  r = 
0.826 with  P < 0.001 (C) and y = 2.21x   0.21;  r = 0.587 with  P < 0.001 (D). 
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blood samples, freshly obtained from the participants, 
with the Ca 2+ ionophore A23187. As shown in  Fig. 6A, C , 
the capacity of blood cells to produce LTB5 and PGE3 
from EPA signifi cantly increased after maximal EPA/DHA 
supplementation and returned to baseline in the follow-up 
period. Nonetheless, the AA-derived LTB4 and PGE2 re-
mained predominant at all stages of the study. The LTB5/
LTB4 ratio ranged between 0.01 and 0.1 and strongly cor-
related with the EPA/AA ratio ( Fig. 6B ). Also, the relative 
formation of PGE3 and PGE2 was linearly correlated with 
the EPA/AA ratio ( Fig. 6D ); however, the formation of 
PGE2 exceeded that of PGE3 almost 20-fold at baseline 
and was still about 8-fold after maximal EPA/DHA supple-
mentation. Ca 2+ ionophore-stimulated thromboxane forma-
tion was largely unaffected by EPA/DHA supplementation 
in most of the participants, and the ratio between AA-
derived thromboxane B2 (TXB2) and EPA-derived 
TXB3 remained unchanged at about 25:1 ( Fig. 6E, F ). 
However, in 5 females and 1 male out of the 19 partici-
pants, this ratio even increased to roughly 100:1 at week 8 
and declined again to 26–31:1 at week 16 . 
 In the urine samples of all participants, TXB2 and TXB3, 
as well as the corresponding 11-dehydro derivatives, were be-
low the limit of quantifi cation of our method (8 and 20 pg for 
the 11-dehydro derivatives and 1.5 and 2 pg/ml urine for 
TXB2 and TXB3, respectively). Urinary excretion of prosta-
cyclin (PGI) derivatives was slightly modulated in response 
to EPA/DHA supplementation (supplementary Table IV). 
However, the ratio between the PGI3- and PGI2-derived hy-
drolysis products (  17 6-keto-PGF1 	 /6-keto-PGF1 	 ) showed 
large inter-individual differences and did not correlate with 
the EPA/AA ratio (supplementary Table IV). 
 Ca 2+ -ionophore treatment did not only induce the for-
mation of leukotrienes and prostanoids, but also specifi -
cally increased the levels of 5-LOX- and 12-LOX-dependent 
monohydroxy-metabolites. After Ca 2+ -ionophore stimula-
tion, the concentrations of free 5-HETE and 5-HEPE were 
approximately 12- and 3-fold higher, respectively, compared 
with the normal circulating levels of these metabolites (com-
pare  Figs. 7A and 4A ). The relative formation of 5-HEPE 
and 5-HETE almost perfectly followed the relative abun-
dance of their precursor fatty acids ( Fig. 7B ). In contrast, 
DHA was obviously not metabolized via the 5-LOX path-
way after Ca 2+ -ionophore stimulation, as indicated by the 
unchanged low levels of 4-HDHA and 7-HDHA ( Fig. 7A vs. 
 Fig. 4A ). 12-LOX-dependent metabolites of AA and EPA, 
as well as DHA, largely increased upon Ca 2+ -ionophore 
stimulation ( Fig. 7C vs.  Fig. 4C ). Compared with their nor-
mal circulating levels, 12-HETE increased 93-fold, 12-
HEPE increased 21-fold, and 14-HDHA increased 13-fold. 
The 12-HEPE/12-HETE ratio strongly correlated with the 
relative abundance of EPA and AA, whereas there was only 
a weak correlation between the 14-HDHA/12-HETE and 
the DHA/AA ratios ( Fig. 7D ). In contrast to its marked 
effects on metabolite formation via the 5-LOX and 12-
LOX pathways, Ca 2+ -ionophore treatment did not stimu-
late the generation of 15-LOX-dependent metabolites 
( Fig. 7E vs.  Fig. 4E ) and also did not increase the levels of 
18-HEPE (data not shown). 
signifi cantly reducing the excretion of the AA-derived me-
tabolites (supplementary Table IV). Among the   -hydroxylase 
products, 20-HETE excretion remained largely unaffected 
by EPA/DHA supplementation. The EPA-derived 20-HEPE 
increased about 3-fold from week 0 to week 8 and returned 
to baseline in the follow-up period (supplementary Table 
IV). 22-HDHA excretion was not signifi cantly modulated by 
EPA/DHA supplementation. 
 Changes in the profi le of LOX- and COX-dependent 
metabolites upon dietary EPA/DHA supplementation 
 5-LOX-dependent monohydroxy-metabolites of EPA 
(5-HEPE) and DHA (4-HDHA and 7-HDHA) signifi cantly 
increased from week 0 to week 8 and declined almost to 
baseline after the participants stopped taking the EPA/
DHA supplement ( Fig. 4A ). The 5-HEPE/5-HETE ratio 
increased linearly with the EPA/AA ratio ( Fig. 4B ). Strong 
correlations were also observed for the 4-HDHA/5-HETE 
ratio ( Fig. 4B ) and for the 7-HDHA/5-HETE ratio (y = 
1.00x   0.01;  r = 0.696 with  P < 0.001, data not shown) 
when plotted against the DHA/AA ratio. The 12-LOX 
pathway that produces 12-HETE from AA, 12-HEPE from 
EPA, and 14-HDHA from DHA responded to EPA/DHA 
supplementation with signifi cant increases in 12-HEPE 
and 14-HDHA formation ( Fig. 4C ). Whereas the 12-HEPE/
12-HETE ratio strongly correlated with the EPA/AA ratio, 
only a weak correlation was detectable between 14-HDHA/
12-HETE formation and the DHA/AA precursor ratio 
( Fig. 4D ). Increased formation of the EPA metabolite, 15-
HEPE, and of the DHA metabolite, 17-HDHA, were the 
characteristic features of the response of the 15-LOX path-
way to EPA/DHA supplementation ( Fig. 4E, F ). Besides 
17-HDHA, 18-HEPE, another precursor of the resolvin 
family, was also strongly increased upon EPA/DHA sup-
plementation ( Fig. 5 ). 
 To study the effects of EPA/DHA supplementation on 
leukotriene and prostanoid formation, we stimulated the 
de novo synthesis of these metabolites by treating whole 
 Fig.  3. Effect of EPA/DHA supplementation on the plasma levels 
of CYP-  -hydroxylase metabolites derived from AA (20-HETE), 
EPA (20-HEPE), and DHA (22-HDHA). Metabolite levels were de-
termined after alkaline hydrolysis and thus represent the sum of 
free and esterifi ed metabolites. Bars show mean ± SEM, n = 19. A 
general linear model for repeated measurements was used for anal-
ysis and signifi cant changes are indicated as: * P < 0.05 versus basal 
level [week 0 (W0)] and # P < 0.05 versus maximum treatment 
[week 8 (W8)]. 
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correlated poorly with the EPA/AA ratio ( Fig. 8B ). Over 
90% of the total 9-HETE and 9-HEPE plasma levels were 
only detectable after alkaline hydrolysis (data not shown), 
indicating that these metabolites circulated primarily in an 
esterifi ed form. The formation of free 9-HETE, but not free 
9-HEPE, was Ca 2+ -ionophore inducible ( Fig. 8C ). 
 9-HETE and 9-HEPE, metabolites presumably produced 
by nonenzymatic oxidation of AA and EPA, were also detect-
able in the plasma samples. 9-HEPE levels increased almost 
2-fold upon EPA/DHA supplementation (week 8) and 
returned to baseline in the follow-up period ( Fig. 8A ). The 
9-HEPE/9-HETE ratio ranged between 0.1 and 0.9 and 
 Fig.  4. Effect of EPA/DHA supplementation on the plasma levels of LOX-dependent monohydroxy-
metabolites. A, B: Plasma levels of 5-LOX-dependent metabolites derived from AA (5-HETE), EPA 
(5-HEPE), and DHA (4-HDHA and 7-HDHA) and their relative abundance in correlation with the corre-
sponding precursor fatty acid ratios (fi lled circles for EPA/AA; open circles for DHA/AA). C, D: Plasma 
levels of 12-LOX-dependent metabolites derived from AA (12-HETE), EPA (12-HEPE), and DHA (14-H-
DHA) and their relative abundance in correlation with the corresponding precursor fatty acid ratios 
(fi lled circles for EPA/AA; open circles for DHA/AA). E, F: Plasma levels of 15-LOX-dependent metabo-
lites derived from AA (15-HETE), EPA (15-HEPE), and DHA (17-HDHA) and their relative abundance in 
correlation with the corresponding precursor fatty acid ratios (fi lled circles for EPA/AA; open circles for 
DHA/AA). Metabolite levels were determined after alkaline hydrolysis and thus represent the sum of free 
and esterifi ed metabolites. Bars show mean ± SEM, n = 19. A general linear model for repeated measure-
ments was used for analysis (A, C, E) and signifi cant changes are indicated as: * P < 0.05 versus basal level 
[week 0 (W0)] and # P < 0.05 versus maximum treatment [week 8 (W8)]. For relative effi ciencies a Pear-
son/Spearman Rho correlation was performed: 5-HEPE/5-HETE, y = 4.02x   0.04,  r = 0.790 with  P < 0.001 
and 4-HDHA/5-HETE, y = 1.89x   0.20,  r = 0.696 with  P < 0.001 (B); 12-HEPE/12-HETE, y = 3.37x   0.05, 
 r = 0.821 with  P < 0.001 and 14-HDHA/12-HETE, y = 3.30x   0.30;  r = 0.493 with  P < 0.001 (D); and 15-
HEPE/15-HETE, y = 1.87x   0.02,  r = 0.795 with  P < 0.001 and 17-HDHA/15-HETE, y = 3.15x   0.32,  r = 
0.688 with  P < 0.001 (F). 
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formation is most responsive to dietary EPA/DHA supple-
mentation compared with the LOX- and COX-initiated 
branches of the human AA cascade. 
 Numerous studies indicated that diets rich in long-chain 
n-3 PUFAs protect against the development of cardiovas-
cular disease ( 30, 31, 34–37 ), although, based on recent 
meta-analysis of clinical trials, considerable controversy 
remains regarding the association of n-3 PUFAs and 
major cardiovascular end points ( 38, 39 ). EPA and DHA 
have anti-infl ammatory, anti-platelet, vasodilatory, hypolipi-
demic, and anti-arrhythmic properties and may thus exert 
pleiotropic benefi cial effects on cardiovascular function 
( 30, 31 ). Uncertainty exists about the target n-3 PUFA 
levels to be adjusted by EPA/DHA supplementation for 
achieving the desired clinical effects. The antiplatelet, an-
ti-infl ammatory, and triglyceride-lowering effects appar-
ently require relatively high doses (3–4 g/day), whereas 
antiarrhythmic effects and reduction of sudden cardiac 
death can be achieved at doses between 0.5 and 1 g/day 
( 31, 37 ). In the GISSI-Prevenzione trial, the risk of sudden 
death was signifi cantly reduced by treating patients after 
myocardial infarction with 1 g of Omacor® per day ( 40 ). 
In the present study, the omega-3 status of the participants 
was quantifi ed using the Omega-3 Index. This index rep-
resents the percentage of EPA + DHA of total fatty acids in 
RBCs and strongly correlates with the content of these n-3 
PUFAs in other tissues and organs including the heart 
( 41 ). The incorporation and washout kinetics of EPA and 
DHA in RBCs proceeds on a time scale of weeks compared 
with the acute diet-induced changes in plasma phospho-
lipids (days) and the very long-lasting effects in adipose 
tissues ( 42, 43 ). In the normal population, the Omega-3 
Index shows a rather broad distribution and ranges from 
less than 4 to 10–12. We intentionally included only sub-
jects with an Omega-3 Index <6 in our study. This pre-
screening allowed us to start EPA/DHA supplementation 
with a group of males and females that were rather uni-
form in terms of having low to median n-3 PUFA levels at 
baseline (the Omega-3 Index of the selected participants 
ranged from 3.6 to 5.9 and was on average 4.9 ± 0.2). Simi-
larly, as reported in a recent study ( 44 ), we observed inter-
individual differences in the response to EPA/DHA 
supplementation that strongly correlated with the product 
of the baseline Omega-3 Index and the dose per kilogram 
of body weight. According to this correlation, those partici-
pants that started with the lowest baseline values and had 
the lowest body weight showed the highest increase of the 
Omega-3 Index. Comparing the omega-3 indices achieved 
after maximal EPA/DHA supplementation, there was a ten-
dency for an increased response of females, who reached an 
Omega-3 Index of 8.8 ± 0.3 at week 8, compared with 8.0 ± 
0.3 in males. However, this apparent sex difference was ob-
viously largely due to the fact that all participants received 
the same dose independent of their body weight that was on 
average lower in females than males. 
 The Omega-3 Index range covered in the present study 
corresponds to the range where EPA/DHA supplementa-
tion is most effective in protecting against fatal cardiac ar-
rhythmia. Based on epidemiological and clinical studies, 
 Effects of EPA/DHA supplementation on clinical 
parameters 
 As summarized in  Table 1 , BMI as well as circulating li-
poproteins and total cholesterol remained unchanged 
over the whole duration of the study. EPA/DHA supple-
mentation caused a signifi cant reduction in plasma triglyc-
eride levels from an average of 1.31 ± 0.2 at week 0 to 0.99 
± 0.1 at week 8 ( Fig. 9A ). After discontinuation of the sup-
plementation, the triglyceride levels returned almost to 
baseline values (1.23 ± 0.2). The triglyceride lowering ef-
fects achieved at week 8 strongly correlated with the basal 
triglyceride levels ( Fig. 9B ). Remarkably, triglyceride levels 
were almost cut in half in those participants who started 
with relatively high values of about 2 mmol/l. In contrast, 
no reduction occurred in participants having already low 
(<1 mmol/l) triglyceride levels at baseline ( Fig. 9B ). 
 The diastolic blood pressure signifi cantly decreased 
from 75.5 ± 1.7 at week 0 to 72.0 ± 1.7 at week 8 and in-
creased again after discontinuation of EPA/DHA supple-
mentation to 73.4 ± 1.8 at week 16 ( Fig. 9C ). Changes in 
systolic blood pressure apparently followed a similar pat-
tern but did not reach signifi cance ( Fig. 9C ). The diastolic 
blood pressure lowering effect showed large inter-individ-
ual differences and tended to be most pronounced in 
those participants who displayed relatively high diastolic 
blood pressure values at baseline ( Fig. 9D ). 
 DISCUSSION 
 The results of the present study demonstrate that the 
human CYP-eicosanoid pathway is highly susceptible to 
changes in the dietary supply of the fi sh oil omega-3 fatty 
acids, EPA and DHA. In particular, EPA/DHA supplemen-
tation caused a pronounced increase in the circulatory and 
urinary levels of EPA- and DHA-derived CYP-epoxygenase 
metabolites. These in vivo fi ndings are in line with the re-
sults of previous in vitro studies on recombinant enzymes 
showing that various human AA-metabolizing CYP isoforms 
accept EPA and DHA as effi cient alternative substrates 
( 1, 19–22 ). Our results also indicate that CYP-eicosanoid 
 Fig.  5. Effect of EPA/DHA supplementation on 18-HEPE forma-
tion. Total plasma levels of 18-HEPE were determined after alkaline 
hydrolysis. Data are given as mean ± SEM, n = 19. A general linear 
model for repeated measurements was used for analysis and signifi -
cant changes are indicated as: * P < 0.05 versus basal level [week 0 
(W0)] and # P < 0.05 versus maximum treatment [week 8 (W8)]. 
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and vicinal diols were reported from studies that treated 
healthy volunteers for 4 weeks with 4 g of an EPA/DHA 
supplement ( 46 ) or asthmatic patients for three weeks with 
4 g EPA + 2 g DHA per day ( 47 ). Even without dietary inter-
vention, the individual differences in the serum concentra-
tions of EPA-derived epoxy- and dihydroxy-metabolites 
correlated well with the EPA content in RBCs, as shown in a 
recent study comparing the metabolite profi les in hyper- 
and normolipidemic men ( 48 ). The levels determined in 
the present study represent the sum of free and esteri-
fi ed metabolites as accessible after alkaline hydrolysis of the 
the Omega-3 Index is inversely correlated with the risk of 
sudden cardiac death and a 10-fold risk reduction may be 
achieved by raising the Omega-3 Index from below 4 to 
more than 8 ( 45 ). Searching for changes in eicosanoid for-
mation that may mediate the antiarrhythmic effect of n-3 
PUFAs, our study shows that raising the Omega-3 Index from 
4 to 8 is accompanied by a strong increase of EPA- and DHA-
derived CYP-epoxygenase metabolites. Actually, EEQs in-
creased almost 4-fold and EDPs 2-fold when comparing the 
plasma levels of these metabolites at week 0 and week 8. 
Similar marked increases of EPA- and DHA-derived epoxides 
 Fig.  6. Effect of EPA/DHA supplementation on leukotriene and prostanoid formation after calcium iono-
phore stimulation. The levels of free metabolites were determined after A23187-mediated stimulation of 
whole blood samples and thus refl ect the metabolic capacity and substrate specifi city of the corresponding 
enzymes expressed in blood cells. A, B: Generated levels of AA-derived LTB4 and EPA-derived LTB5 and the 
relative abundance of LTB5 and LTB4 in correlation with the EPA/AA precursor fatty acid ratio. C, D: Levels 
of AA-derived PGE2 and EPA-derived PGE3 and the relative abundance of PGE3 and PGE2 in correlation 
with the EPA/AA precursor fatty acid ratio. E, F: Levels of AA-derived TXB2 and EPA-derived TXB3 and the 
relative abundance of TXB3 and TXB2 in correlation with the EPA/AA precursor fatty acid ratio. Data are 
given as mean ± SEM, n = 19. A general linear model for repeated measurements was used for analysis (A, C, E) 
and signifi cant changes are indicated as: * P < 0.05 versus basal level [week 0 (W0)] and # P < 0.05 versus maxi-
mum treatment [week 8 (W8)]. For relative effi ciencies, a Pearson/Spearman Rho correlation was per-
formed: LTB5/LTB4, y = 0.58x   0.01,  r = 0.864 with  P < 0.001 (B); PGE3/PGE2, y = 0.16x   0.002,  r = 0.712 
with  P < 0.001 (D); TXB3/TXB2 no correlation (F). 
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 It is noteworthy that the diol/epoxide ratios observed 
in the human circulation did not follow the substrate 
preference of the sEH ( 23 ). For example, the 17,18-
DHEQ/17,18-EEQ ratio was much higher than the 14,15-
DHET/14,15-EET ratio in the human plasma samples, 
whereas the catalytic effi ciency of the human recombi-
nant sEH is three times higher with 14,15-EET than with 
17,18-EEQ as substrate ( 23 ). The mechanisms of how ep-
oxides and diols are released from the tissues and eventu-
ally become constituents of circulating lipoproteins are 
largely unknown, making it diffi cult to explain this fi nd-
ing . Cells preferentially release DHETs while storing the 
EETs ( 9 ), suggesting that certain diols might be overrepre-
sented in the circulation compared with the epoxide/diol 
plasma samples. We used this method because previous 
studies showed that greater than 90% of the plasma EETs 
and related metabolites are esterifi ed to the phospholipids 
of circulating lipoproteins including LDLs, HDLs, and 
VLDLs ( 49, 50 ). Moreover, we considered both the primary 
epoxides and the corresponding vicinal diols formed by 
sEH-mediated hydrolysis as the products that refl ect metab-
olite formation via the CYP-epoxygenase pathway. As tested 
with a subset of our plasma samples, more than 90% of the 
total epoxides derived from AA, EPA, and DHA, and 40–50% 
of the vicinal diols only became detectable after alkaline hy-
drolysis (data not shown), suggesting that the primary and 
secondary products of the CYP-epoxygenase pathways were 
incorporated to different degrees into lipoprotein lipids. 
 Fig.  7. Calcium ionophore stimulated monohydroxy-metabolite formation via LOX enzymes. Shown is the 
formation of free metabolites via 5-LOX (A), 12-LOX (C) and 15-LOX (E) enzymes in whole blood samples 
at baseline [week 0 (W0)], after maximal EPA/DHA-supplementation [week 8 (W8)], and after discontinu-
ation of supplementation [week 16 (W16)]. Bars represent mean ± SEM, n = 19. A general linear model for 
repeated measurements was used for analysis (A, C, E) and signifi cant changes are indicated as: * P < 0.05 
versus basal level (W0) and # P < 0.05 versus maximum treatment (W8). For relative effi ciencies a Pearson/
Spearman Rho correlation was performed: 5-HEPE/5-HETE versus EPA/AA: y = 1.2x   0.02,  r = 0.884 with 
 P < 0.001 and 4-HDHA/5-HETE versus DHA/AA, y = 0.01x   0.00008,  r = 0.351 with  P < 0.001; 7-HDHA/5-
HETE versus DHA/AA: y = 0.02x   0.0008,  r = 0.421 with  P < 0.001 (B). 12-HEPE/12-HETE versus EPA/
DHA: y = 0.73x   0.01,  r = 0.857 with  P < 0.001 and 14-HDHA/12-HETE versus DHA/AA: y = x   0.35   0.01, 
 r = 0.444 with  P < 0.001 (D). 15-HEPE/15-HETE versus EPA/DHA: y = 1.26x   0.01,  r = 0.834 with  P < 0.001 
and 17-HDHA/15-HETE versus DHA/AA: y = 0.93x   0.03,  r = 0.510 with  P < 0.001 (F). 
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leukotriene and COX-dependent prostaglandin E forma-
tion were much less responsive. The AA-derived metabolites 
LTB4 and PGE2 remained clearly predominant and only a 
weak increase of the EPA-derived LTB5 and PGE3 occurred 
upon EPA/DHA supplementation. Least susceptible was 
thromboxane formation, where we could not detect any sig-
nifi cant effect of EPA/DHA supplementation on the TXB3/
TXB2 ratio produced in whole blood samples after Ca 2+ -
ionophore stimulation. The different pathways also varied 
in their response to increased DHA availability ( Fig. 10B ). 
The over proportional increases of 14-HDHA and 17-HDHA 
suggest that DHA was preferred over AA by the 12-LOX and 
15-LOX pathways. 
 The marked elevation of circulating 17-HDHA and 18-
HEPE levels is of particular interest because these DHA- 
and EPA-derived metabolites are the precursors of the 
D- and E-series of resolvins. Resolvins are members of a 
novel class of lipid mediators that have highly potent anti-
infl ammatory and pro-resolution properties ( 52, 53 ). We 
also directly searched for the presence of resolvin D1 in 
plasma samples but, for unknown reasons, were unable to 
detect this metabolite (limit of detection 6 pg/ml), neither 
after extracting the plasma samples with or without prior 
alkaline hydrolysis nor in whole blood samples after Ca 2+ -
ionophore stimulation. 
 The fi rst studies investigating the effect of fi sh oil on eicos-
anoid formation were stimulated by the seminal observation 
ratios in the tissues where these metabolites were primar-
ily produced. 
 The changes in the metabolite profi le produced by 
the CYP-epoxygenase pathway largely exceeded the diet-
induced changes in the relative availability of the precursor 
fatty acids. This result suggests that EPA and DHA were ef-
fi ciently metabolized by the CYP epoxygenases even when 
AA was still present as the predominant long-chain PUFA. 
The ratio between EPA- and AA-derived as well, as DHA- 
and AA-derived epoxy-metabolites, strongly correlated with 
the corresponding precursor PUFA ratios. The slopes of the 
correlation lines indicate that EPA was metabolized to EEQs 
with an 8.6-fold higher effi ciency than AA to EETs, and 
DHA was metabolized to EDPs with a 2.2-fold higher effi -
ciency than AA to EETs. Linear relationships were also ob-
tained when the ratios of EPA-/AA-derived or DHA-/
AA-derived metabolite pairs originating from the LOX and 
COX pathways were plotted against the corresponding pre-
cursor PUFA ratios. As summarized in  Fig. 10A , the slopes 
of the correlation lines suggest that the susceptibility to EPA 
was by far the highest for the CYP-epoxygenase pathway fol-
lowed by 5-, 12-, and 15-LOX-dependent formation of mono-
hydroxy-metabolites. In addition, 18-HEPE, potentially arising 
from nonenzymatic oxidation or CYP-catalyzed monooxy-
genation ( 51 ), was among the EPA-derived metabolites 
showing the highest increase upon EPA/DHA supplemen-
tation. In comparison, 5-LOX/LTA4-hydrolase-dependent 
 Fig.  8. Effect of EPA/DHA supplementation on the formation of nonenzymatic oxidation products. A: 
Plasma levels of AA-derived 9-HETE and EPA-derived 9-HEPE at baseline [week 0 (W0)], after maximal 
EPA/DHA supplementation [week 8 (W8)], and after discontinuation of supplementation [week 16 (W16)]. 
A general linear model for repeated measurements was used for analysis (A, C) and signifi cant changes are 
indicated as: * P < 0.05 versus basal level (W0) and # P < 0.05 versus maximum treatment (W8). B: Correlation 
of the plasma 9-HEPE/9-HETE ratio with the EPA/AA precursor ratio. Metabolite levels in (A) and (B) refer 
to the total amounts of 9-HETE and 9-HEPE as determined after alkaline hydrolysis. C: Presence of free 
9-HETE and 9-HEPE in calcium ionophore treated blood samples. 
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aggregation as its AA-derived counterpart PGI2. Indeed, a 
favorable shift of the thromboxane/PGI ratio to a more 
anti-aggregatory and vasodilatory state was shown in Inu-
its, as well as in persons after long-term intake of high 
amounts of EPA (10–15 g/day) ( 57, 58 ). In the present 
study, the extent of EPA/DHA supplementation was obvi-
ously not sufficient to cause pronounced changes in 
thromboxane and PGI formation. As reviewed recently, 
the (PGI2 + PGI3)/thromboxane ratio starts to increase 
signifi cantly only after achieving EPA/AA ratios higher 
than 0.2:1 ( 59 ), and thus at EPA/AA ratios clearly above 
those maximally reached in the present study (0.15:1). 
in the 1970s of signifi cantly lower myocardial infarction 
rates in Greenland Inuits, who traditionally live on EPA/
DHA-rich seafood, compared with Danish controls ( 54 ). 
Subsequent world-wide epidemiological studies revealed 
the general existence of striking cardiovascular mortality 
differences between populations living on n-6 PUFA- 
versus n-3 PUFA-rich diets ( 55 ). EPA was shown to compete 
with AA to yield less pro-aggregatory (TXA3 vs. TXA2) and 
less pro-infl ammatory eicosanoids (LTB5 vs. LTB4) via the 
COX- and LOX-dependent pathways ( 54, 56 ). In contrast, 
PGI3, formed from EPA in the endothelium, acts with the 
same potency as a vasodilator and inhibitor of platelet 
 Fig.  9. Effect of EPA/DHA supplementation on clinical risk factors. Shown are the changes in triglyceride 
levels (A) and blood pressure (C) and their dependencies on the respective basal levels [(B) and (D), re-
spectively]. Data are given as mean ± SEM, n = 19. A general linear model for repeated measurements was 
used for analysis (A, C) and signifi cant changes are indicated as: * P < 0.05 versus basal level [week 0 (W0)] 
and # P < 0.05 versus maximum treatment [week 8 (W8)]. 
 Fig.  10. Comparison of the susceptibilities of the three branches of the human AA-cascade to dietary EPA/DHA supplementation. This 
fi gure summarizes the linear correlations obtained for the corresponding metabolite precursor fatty acid pairs. The slopes of the correla-
tion lines were taken as a measure for the relative effi ciencies by which EPA and AA (A) or DHA and AA (B) were utilized by the different 
enzymatic pathways of eicosanoid formation. 
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results of the present study expand and specify the general 
hypothesis that dietary EPA/DHA supplementation causes 
pronounced changes in the endogenous eicosanoid profi le 
by providing alternative substrates for all three branches of 
the AA cascade. We focused on the effects of relatively low 
doses of EPA/DHA that were previously shown to mediate 
protection against heart failure and fetal ventricular ar-
rhythmia. Specifi cally, our data show that raising the Ome-
ga-3 Index from about 4 to 8 in humans primarily results in 
a large increase of EPA-derived CYP-epoxygenase metabo-
lites followed by increases of EPA- and DHA-derived hy-
droxy-metabolites including, in particular, the precursors 
of the resolvin family. In contrast, the classical effects on 
leukotriene and thromboxane formation remained rather 
weak or were not expressed at all within the Omega-3 Index 
range covered by the present study. 
 Thus far, it is unclear whether the alterations observed in 
the human circulatory and urinary eicosanoid profi les re-
fl ect corresponding changes in the heart or other organs 
and tissues. Our previous study in rats demonstrated that 
the shift from AA-derived CYP-epoxygenase metabolites to 
EPA- and DHA-derived CYP-epoxygenase metabolites oc-
curred with largely identical effi ciencies in the plasma, 
heart, kidney, liver, lung, and pancreas ( 22 ). Moreover, the 
circulating epoxy-metabolites that are predominantly esteri-
fi ed with lipoprotein lipids may themselves become biologi-
cally active in other tissues after being released by lipoprotein 
lipases ( 81 ). There is increasing evidence for a cardiopro-
tective role of CYP-epoxygenase metabolites from studies 
in animal models of ischemia/reperfusion injury, maladap-
tive cardiac hypertrophy, and arrhythmia ( 12, 24, 82 ). We 
showed that 17,18-EEQ and 19,20-EDP are potential candi-
dates for mediating the antiarrhythmic effect of n-3 PUFAs 
( 22 ). Thus, the formation of these metabolites may provide 
a suitable biomarker for evaluating the outcome of clinical 
studies investigating the effects of EPA/DHA supplementa-
tion in patients after myocardial infarction or suffering 
from atrial fi brillation.  
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